Agios Pharmaceuticals (AGIO) vs. The Competition Head-To-Head Contrast

Agios Pharmaceuticals (NASDAQ: AGIO) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Agios Pharmaceuticals to similar businesses based on the strength of its risk, dividends, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Agios Pharmaceuticals and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agios Pharmaceuticals 0 1 11 0 2.92
Agios Pharmaceuticals Competitors 866 3223 11691 232 2.71

Agios Pharmaceuticals currently has a consensus price target of $75.70, indicating a potential upside of 45.24%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.75%. Given Agios Pharmaceuticals’ rivals higher probable upside, analysts clearly believe Agios Pharmaceuticals has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Agios Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Agios Pharmaceuticals $69.89 million -$198.47 million -8.31
Agios Pharmaceuticals Competitors $284.49 million $33.78 million 79.89

Agios Pharmaceuticals’ rivals have higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Agios Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals -506.39% -69.64% -43.12%
Agios Pharmaceuticals Competitors -5,310.77% -218.27% -39.48%

Risk & Volatility

Agios Pharmaceuticals has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals’ rivals have a beta of 6.07, suggesting that their average share price is 507% more volatile than the S&P 500.

Institutional & Insider Ownership

94.4% of Agios Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Agios Pharmaceuticals rivals beat Agios Pharmaceuticals on 7 of the 12 factors compared.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply